Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma - A phase II study

Anti-Cancer Drugs

Volumn 13, Issue 4, 2002, Pages 395-403

  Späth Schwalbe, Ernst ^a   Lange, Catalina ^a   Genvresse, Isabelle ^a   Krüger, Larissa ^a   Eucker, Jan ^a   Schweigert, Markus ^a   Sezer, Orhan ^a   Budach, Volker ^a   Possinger, Kurt ^a  

^a Vivantes Klinikum Spandau   (Germany)

Author keywords

Aggressive non Hodgkin's lymphoma; Amifostine; CHOP; Elderly; Toxicity

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ONDANSETRON; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPOTENSION; LEUKOPENIA; MALE; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOPROTECTION; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036239037     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200204000-00008     Document Type: Article

References (47)

1. Non-Hodgkin lymphomas
2. Non-Hodgkin's lymphoma time trends: United States and international data
3. Intermediate and high grade non-Hodgkin's lymphoma in the elderly
4. A predictive model for aggressive non-Hodgkin's lymphoma
5. Effect of age on the characteristics and clinical behaviour of Non-Hodgkin's lymphoma patients
6. + lymphoma: Clinico-pathological findings and outcome
7. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma
8. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands
9. Prognosis and management strategies of lymphatic neoplasias in the elderly
10. High grade non-Hodgkin's lymphoma in the elderly - 12 year experience in the Grampian region of Scotland
11. Elderly patients with non-Hodgkin's lymphoma: Population-based results in the Netherlands
12. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
13. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
14. CHOP is the standard regimen in patients ≧ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
15. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma
16. Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma
17. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas
18. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
19. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
20. Cancer and aging: An evolving panorama
21. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
22. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis
23. Randomized trial of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin's lymphoma
24. The cardiotoxicity of chemotherapeutic drugs
25. Doxorubicin-induced cardiomyopathy
26. Small-cell lung cancer in elderly patients: The case for chemotherapy
27. Amifostine: Potential for clinically useful cytoprotection
28. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
29. Bone marrow protection with Amifostine in the treatment of high-risk malignant lymphoma
30. Cytoprotective agents for anthracyclines
31. Effects of amifostine on perfused isolated heart and on acute doxorubicin-induced cardiotoxicity
32. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomised control trial in patients with advanced ovarian cancer
33. Neurologic protection by amifostine
34. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
35. Serious co-morbidity among unselected cancer patients newly diagnosed in the southern part of the Netherlands
36. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
37. What treatment for elderly patients with aggressive lymphoma?
38. Chemoprotective effects of amifostine on hematopoietic and nonhematopoietic tissue
39. Antineoplastic chemotherapy of the older cancer patient
40. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
41. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma
42. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study
43. Elderly aggressive-histology non-Hodgkin's lymphoma: Firstline VNCOP-B regimen experience in 350 patients
44. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: A comparative study
45. Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma: Interim results of a randomized GELA trial
46. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support
47. A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial